Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar deals forge a trio of partnerships

Executive Summary

Aflurry of activity in the biosimilar licensing arena has resulted in three new partnerships being struck. Lupin and Mylan have entered a deal for Mylan to sell the Indian firm’s etanercept candidate in various worldwide territories; Prestige Biopharma and Alvogen have agreed a licensing and supply arrangement on Prestige’s trastuzumab in central and eastern Europe (CEE); and Shanghai Henlius Biotech will allow Accord to sell its trastuzumab in more than 70 countries around the globe.

You may also be interested in...



Accord And Henlius Broaden Trastuzumab Alliance

Shanghai Henlius Biotech and Accord Healthcare have broadened their collaboration on trastuzumab, with the Chinese company licensing its Zercepac biosimilar to Accord in the US and Canada. Meanwhile, Accord has launched a Pelgraz pegfilgrastim pre-filled injector and patient app in the UK.

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.

Alvotech And Prestige Strike Biosimilar Manufacturing Deal

Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

GB000906

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel